Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naptumomab estafenatox
- Development stage
- Phase 3
- Lead developer
- NeoTX Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Naptumomab estafenatox is a recombinant fusion protein used as a tumor-targeting immunotherapy. It consists of the antigen-binding fragment (Fab) of a monoclonal antibody directed towards the tumor-associated antigen 5T4, fused with a mutated form of the superantigen staphylococcal enterotoxin E (SEA/E-120). This fusion protein enhances the immune system's ability to recognize and kill tumor cells by activating T lymphocytes. It is being developed for the treatment of various solid tumors, including non-small cell lung carcinoma, renal cell carcinoma, and pancreatic cancer.
- Brand names
- Anyara
- Other names
- Naptumomab
02
Targets
TCRβ (T-cell receptor beta chain)TPBG (Trophoblast glycoprotein)MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on naptumomab estafenatox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naptumomab estafenatox.